查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2151800

非小細胞肺癌治療市場規模、佔有率和趨勢分析報告：按類型、療法、分銷管道、地區和細分市場預測（2026-2033 年）

Non-small Cell Lung Cancer Therapeutics Market Size, Share & Trends Analysis Report By Type, By Treatment, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

非小細胞肺癌治療市場概述

預計到 2025 年，全球非小細胞肺癌治療市場價值將達到 241 億美元，到 2026 年將成長至 271 億美元，到 2033 年將擴大至 635 億美元，2026 年至 2033 年的複合年成長率為 12.9%。

北美是市場的主要驅動力，預計到 2025 年將佔據最大的銷售佔有率，達到 35.4%。非小細胞肺癌 (NSCLC) 仍然是最常見的肺癌類型，佔全球肺癌病例的近 85%。

在最新臨床指引和分子譜分析在常規實踐中廣泛應用的推動下，治療趨勢正從傳統化療轉向標靶治療和免疫查核點抑制劑。此外，一些國家透過篩檢計畫實現的早期診斷，使得更多患者能夠在疾病早期接受治療。然而，高昂的治療費用、分子診斷資源的可近性差異以及醫療基礎設施的區域差異仍然影響著這些療法的普及。持續的臨床研究和開發，以及監管部門的批准，正在拓展治療選擇，並支持市場的永續發展。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章 非小細胞肺癌治療市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析

第4章 非小細胞肺癌治療市場：按類型分類的業務分析

  • 按類型分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按類型分類，2021-2033 年
  • 鱗狀細胞癌
  • 大細胞癌
  • 腺癌
  • 其他

第5章 非小細胞肺癌治療市場：依療法分類的業務分析

  • 按治療方法分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按治療方法分類，2021-2033 年
  • 化療
  • 標靶治療
  • 免疫療法
  • 其他

第6章 非小細胞肺癌治療市場：依通路分類的業務分析

  • 按分銷管道分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按分銷管道分類，2021-2033 年
  • 醫院藥房
  • 藥局和零售藥房
  • 網路藥房

第7章 非小細胞肺癌治療市場：區域估算與趨勢分析

  • 2025年及2033年區域市佔率分析
  • 區域市場概覽
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第8章 競爭情勢

  • 參與企業概況
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介列表
    • AstraZeneca PLC
    • Merck & Co., Inc.
    • F. Hoffmann-La Roche Ltd.
    • Bristol Myers Squibb.
    • Johnson & Johnson
    • Pfizer Inc.
    • Novartis AG
    • Eli Lilly and Company
    • GSK plc
    • Boehringer Ingelheim
Product Code: GVR-1-68038-703-2

Non-small Cell Lung Cancer Therapeutics Market Summary

The global non-small cell lung cancer therapeutics market size was valued at USD 24.1 billion in 2025 and is projected to grow from USD 27.1 billion in 2026 to USD 63.5 billion by 2033, at a CAGR of 12.9% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 35.4% in 2025. NSCLC remains the most common form of lung cancer, accounting for nearly 85% of all lung cancer cases worldwide.

The treatment landscape has shifted from conventional chemotherapy toward targeted therapies and immune checkpoint inhibitors, supported by updated clinical guidelines and broader molecular profiling in routine practice. Earlier diagnosis through screening programs in selected countries is also increasing the number of patients receiving treatment at earlier disease stages. However, treatment costs, unequal access to molecular diagnostics, and differences in healthcare infrastructure across regions continue to affect therapy adoption. Ongoing clinical research and regulatory approvals are expanding treatment options and supporting sustained market development.

Global Non-small Cell Lung Cancer Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global non-small cell lung cancer therapeutics market report based on type, treatment, distribution channel, and region:

  • Type Outlook (Revenue, USD Billion, 2021 - 2033)
  • Squamous Cell Carcinoma
  • Large Cell Carcinoma
  • Adenocarcinoma
  • Others
  • Treatment Outlook (Revenue, USD Billion, 2021 - 2033)
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Others
  • Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
  • Hospital Pharmacy
  • Drug Store and Retail Pharmacy
  • Online Pharmacy
  • Regional Outlook (Revenue, USD Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Treatment
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Non-small Cell Lung Cancer Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Non-small Cell Lung Cancer Therapeutics Market: Type Business Analysis

  • 4.1. Type Market Share, 2025 & 2033
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Billion)
  • 4.4. Squamous Cell Carcinoma
    • 4.4.1. Squamous Cell Carcinoma Market, 2021 - 2033 (USD Billion)
  • 4.5. Large Cell Carcinoma
    • 4.5.1. Large Cell Carcinoma Market, 2021 - 2033 (USD Billion)
  • 4.6. Adenocarcinoma
    • 4.6.1. Adenocarcinoma Market, 2021 - 2033 (USD Billion)
  • 4.7. Others
    • 4.7.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 5. Non-small Cell Lung Cancer Therapeutics Market: Treatment Business Analysis

  • 5.1. Treatment Market Share, 2025 & 2033
  • 5.2. Treatment Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Billion)
  • 5.4. Chemotherapy
    • 5.4.1. Chemotherapy Market, 2021 - 2033 (USD Billion)
  • 5.5. Targeted Therapy
    • 5.5.1. Targeted Therapy Market, 2021 - 2033 (USD Billion)
  • 5.6. Immunotherapy
    • 5.6.1. Immunotherapy Market, 2021 - 2033 (USD Billion)
  • 5.7. Others
    • 5.7.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 6. Non-small Cell Lung Cancer Therapeutics Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2025 & 2033
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Billion)
  • 6.4. Hospital Pharmacy
    • 6.4.1. Hospital Pharmacy Market, 2021 - 2033 (USD Billion)
  • 6.5. Drug Store and Retail Pharmacy
    • 6.5.1. Drug Store and Retail Pharmacy Market, 2021 - 2033 (USD Billion)
  • 6.6. Online Pharmacy
    • 6.6.1. Online Pharmacy Market, 2021 - 2033 (USD Billion)

Chapter 7. Non-small Cell Lung Cancer Therapeutics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2025 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Billion)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. Canada Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.5. Europe
    • 7.5.1. Europe Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. UK Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Target Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Target Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Target Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Target Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Target Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Target Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Target Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.7. Latin America
    • 7.7.1. Latin America Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Target Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Brazil Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Target Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. Argentina Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Target Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Target Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Target Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Target Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. AstraZeneca PLC
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Merck & Co., Inc.
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. F. Hoffmann-La Roche Ltd.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Bristol Myers Squibb.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Johnson & Johnson
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Pfizer Inc.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Novartis AG
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Eli Lilly and Company
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. GSK plc
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Boehringer Ingelheim
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global non-small cell lung cancer therapeutics market, by region, 2021 - 2033 (USD Billion)
  • Table 4 Global non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 5 Global non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 6 Global non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 7 North America non-small cell lung cancer therapeutics market, by country, 2021 - 2033 (USD Billion)
  • Table 8 North America non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 9 North America non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 10 North America non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 11 U.S. non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 12 U.S. non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 13 U.S. non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 14 Canada non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 15 Canada non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 16 Canada non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 17 Mexico non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 18 Mexico non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 19 Mexico non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 20 Europe non-small cell lung cancer therapeutics market, by country, 2021 - 2033 (USD Billion)
  • Table 21 Europe non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 22 Europe non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 23 Europe non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 24 UK non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 25 UK non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 26 UK non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 27 Germany non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 28 Germany non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 29 Germany non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 30 France non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 31 France non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 32 France non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 33 Italy non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 34 Italy non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 35 Italy non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 36 Spain non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 37 Spain non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 38 Spain non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 39 Norway non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 40 Norway non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 41 Norway non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 42 Denmark non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 43 Denmark non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 44 Denmark non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 45 Sweden non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 46 Sweden non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 47 Sweden non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 48 Asia Pacific non-small cell lung cancer therapeutics market, by country, 2021 - 2033 (USD Billion)
  • Table 49 Asia Pacific non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 50 Asia Pacific non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 51 Asia Pacific non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 52 Japan non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 53 Japan non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 54 Japan non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 55 China non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 56 China non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 57 China non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 58 India non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 59 India non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 60 India non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 61 Australia non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 62 Australia non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 63 Australia non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 64 South Korea non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 65 South Korea non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 66 South Korea non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 67 Thailand non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 68 Thailand non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 69 Thailand non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 70 Latin America non-small cell lung cancer therapeutics market, by country, 2021 - 2033 (USD Billion)
  • Table 71 Latin America non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 72 Latin America non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 73 Latin America non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 74 Brazil non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 75 Brazil non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 76 Brazil non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 77 Argentina non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 78 Argentina non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 79 Argentina non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 80 Middle East & Africa non-small cell lung cancer therapeutics market, by country, 2021 - 2033 (USD Billion)
  • Table 81 Middle East & Africa non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 82 Middle East & Africa non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 83 Middle East & Africa non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 84 South Africa non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 85 South Africa non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 86 South Africa non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 87 Saudi Arabia non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 88 Saudi Arabia non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 89 Saudi Arabia non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 90 UAE non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 91 UAE non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 92 UAE non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 93 Kuwait non-small cell lung cancer therapeutics market, by type, 2021 - 2033 (USD Billion)
  • Table 94 Kuwait non-small cell lung cancer therapeutics market, by treatment, 2021 - 2033 (USD Billion)
  • Table 95 Kuwait non-small cell lung cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)

List of Figures

  • Fig. 1 Non-small cell lung cancer therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Non-small cell lung cancer therapeutics market dynamics
  • Fig. 11 Non-small cell lung cancer therapeutics market: Porter's five forces analysis
  • Fig. 12 Non-small cell lung cancer therapeutics market: PESTLE analysis
  • Fig. 13 Type market, 2021 - 2033 (USD Billion)
  • Fig. 14 Squamous cell carcinoma market, 2021 - 2033 (USD Billion)
  • Fig. 15 Large cell carcinoma market, 2021 - 2033 (USD Billion)
  • Fig. 16 Adenocarcinoma market, 2021 - 2033 (USD Billion)
  • Fig. 17 Others market, 2021 - 2033 (USD Billion)
  • Fig. 18 Treatment market, 2021 - 2033 (USD Billion)
  • Fig. 19 Chemotherapy market, 2021 - 2033 (USD Billion)
  • Fig. 20 Targeted therapy market, 2021 - 2033 (USD Billion)
  • Fig. 21 Immunotherapy market, 2021 - 2033 (USD Billion)
  • Fig. 22 Others market, 2021 - 2033 (USD Billion)
  • Fig. 23 Distribution channel market, 2021 - 2033 (USD Billion)
  • Fig. 24 Hospital pharmacy market, 2021 - 2033 (USD Billion)
  • Fig. 25 Drug store and retail pharmacy market, 2021 - 2033 (USD Billion)
  • Fig. 26 Online pharmacy market, 2021 - 2033 (USD Billion)
  • Fig. 27 Non-small cell lung cancer therapeutics market revenue, by region
  • Fig. 28 Regional marketplace: Key takeaways
  • Fig. 29 North America non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 30 U.S. country dynamics
  • Fig. 31 U.S. non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 32 Canada country dynamics
  • Fig. 33 Canada non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 34 Mexico country dynamics
  • Fig. 35 Mexico non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 36 Europe non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 37 UK country dynamics
  • Fig. 38 UK non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 39 Germany country dynamics
  • Fig. 40 Germany non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 41 France country dynamics
  • Fig. 42 France non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 43 Italy country dynamics
  • Fig. 44 Italy non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 45 Spain country dynamics
  • Fig. 46 Spain non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 47 Norway country dynamics
  • Fig. 48 Norway non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 49 Sweden country dynamics
  • Fig. 50 Sweden non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 51 Denmark country dynamics
  • Fig. 52 Denmark non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 53 Asia Pacific non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 54 Japan country dynamics
  • Fig. 55 Japan non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 56 China country dynamics
  • Fig. 57 China non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 58 India country dynamics
  • Fig. 59 India non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 60 Australia country dynamics
  • Fig. 61 Australia non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 62 South Korea country dynamics
  • Fig. 63 South Korea non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 64 Thailand country dynamics
  • Fig. 65 Thailand non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 66 Latin America non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 67 Brazil country dynamics
  • Fig. 68 Brazil non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 69 Argentina country dynamics
  • Fig. 70 Argentina non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 71 MEA non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 72 South Africa country dynamics
  • Fig. 73 South Africa non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 74 Saudi Arabia country dynamics
  • Fig. 75 Saudi Arabia non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 76 UAE country dynamics
  • Fig. 77 UAE non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 78 Kuwait country dynamics
  • Fig. 79 Kuwait non-small cell lung cancer therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 80 Company categorization
  • Fig. 81 Company market position analysis
  • Fig. 82 Strategic framework